BioBusiness

Feliza Mirasol is the science editor for 

Articles

With the completion of its acquisition of Morphic, Lilly expands its immunology pipeline to include Morphic's oral integrin therapies to address inflammatory bowel disease.

Lilly Completes $3.2 Billion Acquisition of Morphic, Boosting Its IBD Pipeline

Under a deal worth potentially up to $1.3 billion, Merck, known as MSD outside of the United States and Canada, will acquire CN201, a next-generation bispecific antibody, from Curon Biopharmaceutical. 

Merck Plans to Acquire Investigational Bispecific Antibody from Curon Biopharmaceutical in $1.3 Billion Deal

With this acquisition, AbbVie gains Cerevel’s clinical-stage assets that complement AbbVie's emerging neuroscience pipeline as well as branded products for treating psychiatric disorders, migraine, and Parkinson's disease.

AbbVie Completes $8.7 Billion Acquisition of Cerevel Therapeutics to Boost Neurological Pipeline

Editor of Pharmaceutical Technology Europe

The addition of BIOVECTRA’s biologics capabilities to accelerate drug development and manufacturing will allow Agilent to expand its end-to-end offerings for biopharma services. 

Agilent Expands Biopharma Offerings with BIOVECTRA Acquisition

The acquisition adds a Phase III therapeutic peptide candidate to AstraZeneca’s late-stage pipeline for rare diseases.

AstraZeneca Strengthens Rare Disease Portfolio with Amolyt Pharma Acquisition

The acquisition of EyeBio adds a late-phase antibody drug candidate for diabetic macular edema and neovascular age-related macular degeneration to Merck’s pipeline. 

Merck Completes EyeBio Acquisition, Strengthens Eye Disease Portfolio

The acquisition adds NM26, a Phase II-ready bispecific antibody for treating atopic dermatitis, to Johnson & Johnson’s immune-mediated and inflammatory disease portfolio.

Johnson & Johnson Completes Numab Subsidiary Acquisition, Boosts Bispecific Antibody Pipeline

With the acquisition, Olink will join Thermo Fisher’s Life Sciences Solutions business.

Thermo Fisher Scientific Completes Olink Acquisition, Boosts Proteomics Capabilities

The Celsius Therapeutics acquisition will add CEL383, a potential first-in-class anti-TREM1 antibody for IBD, to AbbVie’s portfolio.

AbbVie Acquires Celsius Therapeutics, Gains Anti-Inflammatory Disease Antibody

With the Proteologix acquisition, Johnson & Johnson gains two bispecific antibody early phase assets for immune-mediated diseases.

Mergers and Acquisitions